Engimmune is an immunotherapy company utilising cutting-edge methods for the development of T-cell receptor (TCR)-based immunotherapies including T cell therapies and biologics. By applying our unique protein engineering toolbox we have established and continue to develop proprietary high-throughput technology platforms enabling the discovery of highly potent and safe TCR-based cell therapies and biotherapeutics, thus covering the entire TCR discovery value chain.
Operating as a platform technology and product development company, our vision is to become a globally leading provider of best-in-class TCR-based therapeutics for the treatment of serious human diseases with high unmet medical need, with a particular focus on oncology.
Engimmune is based in a brand new science park in Allschwill, Basel in Switzerland
Company Details
- Employees
- 27
- Founded
- 2021
- Address
- Hegenheimermattweg 167a, Allschwil,basel-Country 4123,switzerland
- Industry
- Biotechnology
- Website
- http://www.engimmune.com
- HQ
- Allschwil, Basel-Country
Engimmune Therapeutics Questions
Engimmune Therapeutics's website is http://www.engimmune.com
Engimmune Therapeutics's LinkedIn profile is https://ch.linkedin.com/company/engimmune-therapeutics
Engimmune Therapeutics has
27 employees.
View email and phone details for 27
employees at Engimmune Therapeutics.
Engimmune Therapeutics's industry is
Biotechnology
Engimmune Therapeutics's top competitors are
Noema Pharma,
Endogena Therapeutics, Inc.,
Tolremo Therapeutics,
Cdr-Life Inc.,
Araris Biotech Ag,
Alentis Therapeutics,
Synendos Therapeutics Ag,
Cutiss Ag,
Forx Therapeutics,
Haya Therapeutics.
Engimmune Therapeutics's categories are Biotechnology
Engimmune Therapeutics's founding year is 2021
